Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS (September 29, 2022).
AMX0035 is a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA). Many studies showed TUDCA is beneficial for PD.
RELYVRIO (previously known as AMX0035 in the U.S.) is an oral, fixed-dose combination therapy for the treatment of adults with ALS
RELYVRIO significantly slowed the loss of physical function in a randomized, placebo-controlled clinical trial in ALS
alzforum.org/therapeutics/r...
amylyx.com/media/amylyx-pha...
youtube.com/watch?v=Cr_fovl...
PB Phenylbutyrate
PB was also reported to protect against neurodegeneration in models of α-synuclein toxicity and Parkinson’s disease (Sturm et al., 2016; Ono et al., 2009).
UDCA/TUDCA
The UP-Study confirmed UDCA is beneficial to PD.
healthunlocked.com/cure-par...
TUDCA reduced amyloid deposition and improved cognition in APP/PS1 mice (Nunes et al., 2012). It also improved pathology and behavior in mouse models of Parkinson’s disease, HD, and ALS (reviewed by Ackerman and Gerhard, 2016).